Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT001 for lateral canthal lines
NCT01064518Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Jan 2010
- Primary completion
- Jul 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daxibotulinumtoxinA in lateral canthal rhytides, sponsored by Revance Therapeutics. Started Jan 2010; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT01064518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01064518.